Thyroid disorders are common in women of reproductive age. 1 Overt thyroid disease carries an increased risk of adverse pregnancy outcomes including miscarriages, stillbirths and neurointellectual impairment in the offspring.
| PHYS IOLOG IC AL ADAP TATIONS OF THYROID FUN C TI ON IN PREG NAN C Y
Normal pregnancy is characterized by a series of dynamic and highly orchestrated alterations in thyroid hormone economy ( Figure 1 ). 4, 9 These changes are set in motion from the early postconception period and adapt through gestation to increase foetal thyroid hormone delivery in the face of increased iodine requirements and peripheral hormone metabolism.
| Increase in thyroid hormone production
Serum thyroxine-binding globulin (TBG) concentrations start to rise from 6-week gestation primarily due to oestrogen-induced increase in hepatic TBG synthesis. 9 TBG is the major thyroid hormone transport protein in pregnancy, and consequently, total T4 and T3 concentrations increase in parallel, peaking by mid-gestation. Levels of free thyroid hormones may fall to a small degree but are generally maintained within the normal range in healthy women with adequate iodine nutrition and thyroid function. 10 Increased thyroid hormone production also results from the thyroid stimulatory actions of placental-derived human chorionic gonadotropin (hCG). hCG has an identical α-subunit to TSH, and so acts on TSH receptors on thyroid follicular cells to increase thyroidal T3 and T4 output. The increase in thyroid hormone production is in turn accompanied by a fall in serum TSH via pituitary-thyroid feedback and trough TSH concentrations are reached by 10-12 weeks. Lastly, increased thyroid hormone requirements are amplified by thyroid hormone peripheral metabolism by the type III inner-ring deiodinase (D3), abundantly expressed in placental tissue. 9 
| Increase in iodine requirements
Iodine requirements increase in pregnancy primarily due to increased renal clearance with additional foeto-placental losses in later gestation. The thyroid gland compensates for these losses by increasing thyroidal iodide uptake and clearance. Pregnant women with sufficient iodine nutrition are able to seamlessly implement these adaptive mechanisms, but in iodine-deficient states, these changes may fail to deliver adequate thyroid hormones to the foetus. Population iodine nutrition remains highly variable, and even in countries with iodine-sufficient status, some pregnant women do not achieve the minimum recommended daily iodine intake of 250 mcg daily.
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European and American endocrine society guidelines recommend antenatal supplementation of 150 mcg of iodine daily, but specific recommendations in the UK are lacking.
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| Laboratory implications
The physiological changes described above result in a downward shift of gestational TSH reference intervals. This change is most marked in the first trimester and varies with race and ethnicity. Current guidelines recommend the use of trimester-specific normative values derived from a representative healthy pregnant population, but such data are not widely available. A pragmatic TSH upper limit of 2.5 mU/L was previously advocated, but recent data now show this to be too low. 14 One approach suggested in the current guidelines of the American Thyroid Association (ATA) is to set the pregnancy reference range at 0.5 and 0.4 mU/L below the upper and lower nonpregnant reference range, respectively, reflecting the anticipated magnitude of the TSH drop. 12 With respect to FT4, the commonly used immunoassays are prone to method-dependent bias in pregnancy due to 
| Overt hypothyroidism
Overt hypothyroidism (ie, low FT4 and elevated TSH) affects 0.3%-0.5% of the population and is 10 times more prevalent in females than in males. 16 In iodine-replete countries, hypothyroidism is predominantly due to Hashimoto's thyroiditis characterized by the presence of circulating thyroid-specific antibodies namely thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) antibodies. Other common causes include thyroidectomy and radioiodine therapy for benign and malignant thyroid disease, and globally, iodine deficiency remains relevant in areas with severe deficiency. Uncorrected overt hypothyroidism increases the risk of adverse pregnancy outcomes such as miscarriages, eclampsia, anaemia and preterm births. 17, 18 The effect of maternal hypothyroidism also affects neuro-intellectual and behavioural development in the child. 2, 17, 18 There is consensus that overt hypothyroidism in pregnancy should be corrected although prospective controlled trials are lacking and would be unethical in the light of current understanding.
However, we can surmise from available observational data that it is beneficial to correct overt hypothyroidism in pregnant women.
Several small prospective open-labelled studies have shown that correction of overt hypothyroidism to TSH levels within the reference range yields significant gains in reducing foetal loss. 5, 19 An analysis of a large community database of levothyroxine-treated women showed an incremental increase in miscarriage risk in association with rising TSH strata, with the highest risk seen at early gestation TSH concentrations exceeding 10 mU/L (OR: 3.95, 95% CI: 1.87, 8.37). 
| Preconception management of hypothyroidism
The goal of preconception management is to correct hypothyroidism, provide prepregnancy counselling and pre-emptively increase levothyroxine dose on conception (Table 1 ). In the absence of a functioning thyroid gland, most women with hypothyroidism will require an increase in levothyroxine dose to meet gestational demands. Studies report a 30%-50% increase in requirements although the magnitude of this increase and the proportion of patients requiring dose increases are more variable. [20] [21] [22] In practice, 25%-50% of women have TSH values outside the references ranges in early pregnancy 7, 23, 24 in part due to the postconception TSH rise [24] [25] [26] but also a reflection of inadequate thyroid hormone replacement in the general population. 27, 28 Women with a new diagnosis of hypothyroidism should be commenced on fullreplacement doses of levothyroxine (0.8-1.6 mcg/kg/d), and advice should be provided on the importance of treatment adherence and the need to optimize thyroid hormone replacement before conception.
Patients should be reassured that levothyroxine is safe in pregnancy and that satisfactory pregnancy outcomes are achieved with adequate replacement. Liothyronine or desiccated thyroid preparations are not recommended in pregnancy as T3 is wholly degraded in the placenta.
The preconception TSH target for levothyroxine-treated women should be similar to the first trimester target, that is between the lower reference limit and 2.5 mU/L. 12 Other limits may be more appropriate where gestation-specific reference ranges are available. 12 
| Subclinical hypothyroidism
Unlike overt hypothyroidism, it is less certain whether patients with subclinical hypothyroidism (ie, elevated TSH with normal FT4 levels) should be treated with levothyroxine. Subclinical hypothyroidism affects 2%-3% of pregnant women although higher rates are reported when stringent upper TSH limits are applied. 29 Progression rates from subclinical to overt disease are 2%-5% per year and are amplified in individuals with positive TPOAb or TSH concentration >10 mU/L. 16 In pregnancy, a quarter of women with subclinical hypothyroidism have persistent TSH elevation 5 years after delivery.
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The foeto-maternal risks associated with overt hypothyroidism are also seen with subclinical hypothyroidism 5 and have been addressed in numerous largely retrospective studies marked by disparities in diagnostic TSH thresholds, study end-points and timing of assessments. 1,31,32 Meta-analysis of these studies suggests a significant risk of miscarriage and preterm loss in women with gestational subclinical hypothyroidism. 2 Recent data from a Chinese national health programme (n = 184 611 women) showed that even a TSH >2.5 mU/L in the 6 months before conception was associated with small but significant risks of miscarriages and preterm delivery.
32
However, despite the wealth of observational data, only a few interventional trials have been published ( Two well-conducted randomized controlled trials investigated the benefits of maternal screening and levothyroxine treatment on child cognition. 37 The controlled antenatal thyroid screening study (CATS) randomized 21,846 pregnant women to a screening or control group and treated the screened group with levothyroxine if they had subclinical hypothyroidism or hypothyroxinaemia. 37 IQ scores evaluated at 3 years were not different between offspring of treated and untreated women. In the second study, 677 women with subclinical hypothyroidism and 526 with hypothyroxinaemia were randomly assigned to receive levothyroxine or placebo. 38 Similarly, no differences in IQ were observed between children of treated and untreated mothers tested from 3 to 5 years of age. Pooled analysis of both trials 39 as well as a follow-up evaluation of the CATS child cohort at 9 years also failed to show differences in IQ scores. 40 Several explanations have been proposed to reconcile these findings including late treatment initiation (median gestational age: 13-18 weeks), possible overtreatment (CATS cohort) and high loss to follow-up (CATS cohort).
Thus, pending further trials, there is insufficient evidence to support a consistent therapeutic policy for subclinical hypothyroidism in pregnancy. In agreement with most international guidelines, we recommend treating women with positive antibodies, TSH >10 mU/L, and women with other risk factors for thyroid dysfunction (Table 3) .
Women with infertility or recurrent pregnancy loss should be offered levothyroxine on the basis that treatment could potentially improve live delivery rates 41, 42 (Table 2) . Furthermore, hypothyroidism can be induced or worsened by controlled ovarian stimulation used in preparation for artificial reproduction technology (ART) procedures. The mechanism of hypothyroidism in this setting is believed to be due to the oestrogen surge which increases TBG concentrations thereby exaggerating the fall in free thyroid hormone levels and the compensatory rise in TSH. 
| ISOL ATED HYP OTHYROXINAEMIA
Isolated hypothyroxinaemia refers to the biochemical finding of a low FT4 in conjunction with a normal TSH concentration. 44 The aetiology of this condition is unclear but contributory factors in pregnancy include iodine deficiency, thyroid autoimmunity, assay techniques and maternal characteristics such as age, body mass index and coexistent diabetes. 44, 45 The prevalence depends on the diagnostic FT4 threshold as well as the iodine nutrition status of the population and ranges from 1% to 10% in iodine-sufficient countries to 20%-30% in deficient areas.
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There is evidence that maternal hypothyroxinaemia adversely affects child cognitive and behavioural development. Pop and lowing an open discussion regarding the lack of evidence in this area.
| EUTHYROID THYROID AUTOIMMUNIT Y
About 10% of pregnant women have positive thyroid antibodies without thyroid dysfunction although prevalence rates vary according to ethnicity and iodine nutrition. 1 Thyroid autoimmunity is more common in women with infertility and recurrent pregnancy loss, 53 and about a fifth of untreated antibody-positive women develop an elevated TSH during the course of pregnancy 6 indicating a degree of thyroid hormone deficiency. Observational studies have
shown an increased risk of miscarriages, preterm birth and child neuro-intellectual deficits in pregnant women with thyroid antibodies (TPOAb) 54 although this association was not confirmed in some studies. 55 However, the results of meta-analyses support an overall increased risk of pregnancy loss in association with maternal thyroid autoimmunity in spontaneous as well as assisted pregnancies.
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A cause-effect relationship is unproven but suggested mechanisms include the possibility of innate thyroid hormone deficiency, induction of a diffuse autoimmune process that promotes rejection of the foetal allograft and the confounding effects of older age in antibody-positive women. 59 Furthermore, TPOAb-positive women with a higher risk of premature delivery have been shown to exhibit dissociation between hCG and FT4 concentrations suggesting that
TPOAb may impair the thyroidal response to hCG.
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Whether levothyroxine can prevent foetal loss in antibodypositive women is unproven. Negro et al 6 showed that miscarriage rates in untreated euthyroid TPOAb-positive pregnant women were higher than in antibody-positive women who received levothyroxine (13.8% vs 3.5%). In a similarly designed study, Nazarpour et al 62, 63 saw a reduction in preterm delivery rates in treated antibody-positive women. 61 Other trials did not confirm these benefits, and levothyroxine had no impact on pregnancy loss in TPOAb-positive women with TSH<2.5 mU/L. 64 Thus, there is currently no strong evidence to support routine levothyroxine therapy for women with thyroid autoimmunity. Nonetheless, thyroid function should be monitored through pregnancy due to the risk of thyroid dysfunction. Two randomized controlled trials, the UK TABLET study and the T4Lifetrial in Holland, are currently investigating the effects of Levothyroxine on life birth rates in women with recurrent pregnancy loss.
| HYPERTHYROIDIS M
Hyperthyroidism or excess thyroid hormone production is diagnosed in 0.1%-1.0% of all pregnancies in iodine-sufficient countries. 4, 65 The vast majority of cases are due to Graves' disease although other causes such as solitary and multiple autonomously functioning nodules are occasionally seen in pregnancy. 65 In Graves' disease, hyperthyroidism results from unregulated stimulation of the TSH receptor by TRAbs, the pathological disease hallmark. Three well-established therapies for hyperthyroidism namely antithyroid drugs, radioactive iodine and thyroidectomy have been available for over half a century. 67 However, therapeutic options in pregnancy are limited to antithyroid drugs as radioactive iodine therapy is contraindicated in pregnancy and thyroidectomy is rarely used due to the risk of surgical morbidity and foetal exposure to anaesthetic gases. In pregnancy, the combination of maternal hyperthyroidism, circulating maternal TRAbs and antithyroid drug therapy presents significant threats to foetal and maternal wellbeing ( Figure 2 ).
| Maternal hyperthyroidism
Uncontrolled hyperthyroidism exerts well-recognized effects that include miscarriages, stillbirths, intrauterine growth retardation, maternal hypertension and heart failure. 68, 69 These associations were originally documented in early hospital series 70 and have subsequently been confirmed in large population data sets. 71 Women with severe uncontrolled hyperthyroidism may also develop cardiovascular complications including hypertension, arrhythmias and cardiac failure. 72 Adverse effects are typically seen in association with overt hyperthyroidism (elevated FT4 and suppressed TSH) but not with subclinical hyperthyroidism (normal FT4 and suppressed TSH) which in most instances reflects the normal physiological adaptations in pregnancy.
| Maternal TRAbs
In pregnancy, circulating maternal TRAbs cross the placenta and can induce foetal thyroid dysfunction through actions on TSH receptors on the foetal thyroid gland. 74, 75 Maternal TRAbs are predominantly stimulatory and cause foetal hyperthyroidism and goitre although hypothyroidism occasionally occurs from the action of TRAbs with inhibitory properties. 75 The prevalence of foetal hyperthyroidism is difficult to ascertain, but hyperthyroidism occurs in about 1%-5%
of neonates of mothers with Graves' disease. 76 Although neonatal hyperthyroidism is typically transient, it can result in significant morbidity with occasional fatality if unrecognized. 76 An important consideration is that pregnant women with previous Graves' disease who were rendered hypothyroid by radioiodine therapy or surgery may continue to harbour TRAbs thus placing the foetus at risk of thyroid dysfunction. 77 In a 5-year prospective study, persistence of TRAb levels 18 months after therapy was seen in 75% of radioiodinetreated patients compared to 30% of postsurgical patients and 3% of women rendered euthyroid with antithyroid drugs. 77 
| Antithyroid drugs
The thionamide compounds namely methimazole (MMI), its pro-drug derivative, carbimazole (CMZ) and propylthiouracil (PTU) represent the mainstay of therapy for hyperthyroidism in pregnancy. 78 These compounds reduce thyroid hormone secretion through inhibition of thyroid peroxidase coupling and iodination of tyrosine residues on thyroglobulin. 78 They also have immunosuppressive properties, and in large doses, PTU blocks peripheral T4 to T3 conversion. 78 CMZ is available in the UK while MMI is prescribed in the United States and continental Europe. Outside of pregnancy, MMI or CMZ (CMZ/MMI) is the first-line therapy due to a more favourable pharmacokinetic and safety profile. Both drugs cross the placenta to the same extent and are secreted in breast milk with negligible effects on the thyroid function of breast-fed neonates.
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About 1%-5% of patients treated with antithyroid drugs report minor reactions such as rash and fever, which resolve with discontinuation and switching to an alternative drug. 79 Agranulocytosis is a potentially more serious problem that occurs in 0.1%-0.2% of antithyroid drug users particularly patients on high-dose regimens. It develops abruptly and is difficult to predict even with routine blood count monitoring. Affected patients should stop thionamides, and treatment with broad-spectrum antibiotics is usually required.
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PTU is associated with a potentially fatal liver toxicity that occurs in about 1 per 1000 treated pregnant women per year. 80 In one US series, 22 episodes of PTU-related liver failure comprising 9 deaths and 5 liver transplants were observed over a 20-year period. 81 The course of PTU-related hepatotoxicity can be catastrophic in pregnancy, and a review of 6 reported cases revealed one fatality and 2 liver transplants. 79 Early recognition of cases offers the best hope of survival although the risk of hepatotoxicity is difficult to predict from clinical and biochemical monitoring.
Another concern regarding thionamide use in pregnancy is the risk of congenital anomalies. CMZ/MMI is associated with CMZ or MMI embryopathy, a classic cluster of anomalies comprising aplasia cutis, choanal atresia, trachea-oesophageal fistula and dysmorphic facial features. 82 This association was originally reported in small case series, but the use of large disease registries has now revealed a more varied phenotype. 83 Analysis of a Danish birth registry showed a prevalence of birth defects following intrauterine exposure to PTU and CMZ/MMI which was 2%-4% higher than in unexposed children. 84 Furthermore, a less severe pattern of anomalies was observed for PTU exposure comprising renal tract and head and neck anomalies. 84 The increased risk of birth defects in association with PTU as well as CMZ/MMI exposure has since been confirmed in 2 meta-analysis published in 2015 85, 86 as well as in a recently published study from a large Korean health database. 87 The above considerations have therefore shaped current policy on the management of gestational hyperthyroidism with the goal being to control hyperthyroidism and at the same time limit foeto-maternal drug exposure. 12 Antithyroid drugs should be used at the least effective dose that maintains normal thyroid status. Furthermore, because
Graves' hyperthyroidism may undergo remission during the course of F I G U R E 2 Adverse effects of hyperthyroidism in pregnancy on foetal and maternal well-being pregnancy, presumably as a result of a decline in thyroid autoimmu- Figure 3) . 67, 91 It is important that pregnancy is avoided for 6 months after radioiodine treatment due to the potential for foetal harm from radioiodine exposure. 12, 15 Total thyroidectomy may be preferable in individuals with high risk of relapse as thyroidectomy is usually although not invariably followed by disappearance of circulatory TRAbs.
| Preconception management of hyperthyroidism
77
Several approaches can be adopted in women who are actively trying to conceive while still undergoing treatment with antithyroid drugs. 92 One option is to switch such women from CMZ/MMI to PTU as PTU is the preferred treatment in the first trimester. 15 Alternatively, MMI/CMZ may be continued up till conception and then switched as early as possible on conception to PTU. This approach restricts the use of PTU to the first trimester of pregnancy thus reducing the risk of PTU-related hepatotoxicity. 15 The third approach is to stop antithyroid drugs on conception in women with a low risk of relapse, that is negative TRAb levels, no goitre no ophthalmopathy and low-dose thionamide requirements 15 ( Figure 3) . 
| UNIVER SAL PRECON CEP TION SCREENING
Current international guidelines do not recommend routine thyroid screening in pregnancy or the preconception period, except in women at risk of thyroid dysfunction, the so-called case-finding strategy (Table 3) . 12 The rationale behind this approach is that the bulk of thyroid disorders in pregnancy are asymptomatic subclinical disease with no proven benefits of therapy and that screening could generate anxiety and present a risk of harm from overtreatment. 93 The argument in favour of universal screening however is that thyroid dysfunction is common in pregnancy, adversely affects foeto-maternal outcomes and is easily treated with established cost-effective therapies. 93 Furthermore, a third of women with gestational thyroid dysfunction are not identified with existing case-finding strategies 94 which is less cost-effective than universal screening. 95 In reality, current clinical practice is approaching universal screening driven by increasing public and clinician awareness. 96 In one hospital study, 85% of pregnant women had thyroid tests performed 96 and almost half of European thyroidologists reported that they screened all women in pregnancy. 97 Further studies are required to understand the reach and impact of existing screening strategies.
| CON CLUS IONS
The threats to foetal and maternal well-being posed by thyroid dysfunction in pregnancy can be reduced by thoughtful and pragmatic preconception planning and treatment. Endocrinologists and general clinicians will increasingly encounter women of child-bearing age with thyroid disorders many of whom will require preconception advice. Administrative frameworks for such services will vary according to local resources, but as many pregnancies are unplanned, clinicians should opportunistically address future pregnancy during routine clinical encounters. More research is needed to determine best policy in women with subclinical hypothyroidism, hypothyroxinaemia and thyroid autoimmunity as well as safe strategies for antithyroid drug use in the peri-conception period. Furthermore, the controversies regarding thyroid disease screening are unlikely to be resolved without additional adequately powered interventional trials. The striking scarcity of controlled trials in this area reflects the enormous obstacles in recruitment and retention. In particular, the few studies published to date have been plagued by the challenges of late recruitment and initiation of therapy. The design of future trials will therefore be central to their success, and a preconception recruitment approach stands to guarantee optimal thyroid hormone delivery during the critical period of foetal development. While this will be challenging to achieve, recruitment hurdles could be overcome through collaborative multinational efforts.
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